Pancreatic health
Pancreatic Health
Potential pancreatic cell protection and endpoints in related human trials
Pancreatic inflammation and tissue damage decreased in sulforaphane treated mice. Related human trials addressed glucose and insulin secretion markers in prediabetes and intake feasibility in pancreatic cancer.
Read pancreatic cell protection research- 3 studies
- Key studies by question
- Cell protection
- Observed in animals
- Blood glucose and survival
- Evaluated in humans
Pancreatitis Animal Study · Observed Changes
Observed in mice given sulforaphane
- Pancreatic inflammation
- Decrease
- Tissue injury
- Less damage
Animal experiments with induced acute and recurrent pancreatitis
Read Mareninova · 2026 →Pancreatic health · research results at a glance
3 studies
Pancreatic cell protection · animal and cell studies
| Study and participants | Intake and observation | Findings and context |
|---|---|---|
| Mareninova · 2026 Mouse · nonalcoholic and alcohol-related models |
Sulforaphane 50 mg/kg/day · intraperitoneal injection Three-day pretreatment or dosing between two attacks | Reduced pancreatic inflammation and injury in animalsFinding: Inflammation and tissue injury fell in sulforaphane treated mice. Injury from a second induced pancreatitis episode was also reduced when treatment began after the first episode. Context: A study of mice with induced pancreatitis and isolated pancreatic cells. |
Blood glucose and insulin secretion markers · human trials
| Study and participants | Intake and observation | Findings and context |
|---|---|---|
| Dwibedi · 2025 89 adults with prediabetes assigned |
SFN 150μmol/day · 12 weeks extract 35 / placebo 39 participants | Metabolic markers in adults with prediabetesFinding: After 12 weeks, fasting glucose averaged 0.2 mmol/L lower than placebo. An estimate of insulin secreting cell function did not differ across the full groups. Context: Eighty nine adults with prediabetes were randomized and 74 were analyzed. |
Pancreatic cancer patients · intake feasibility
| Study and participants | Intake and observation | Findings and context |
|---|---|---|
| Lozanovski · 2020 Germany · 40 patients with advanced pancreatic cancer |
Sprout powder capsules · up to one year 15 capsules daily: sulforaphane 90mg + glucoraphanin 180mg | A pilot trial of 40 patients undergoing chemotherapyFinding: Sprout capsules were added during chemotherapy, but the survival difference was not statistically significant. The burden of taking 15 capsules per day and high dropout were also reported. Context: A pilot trial of feasibility and tolerability during chemotherapy. |
Sources
- Mareninova et al. 2026. American journal of physiology. Gastrointestinal and liver physiology. 331:G348-G364.DOI 10.1152/ajpgi.00032.2026
- Dwibedi et al. 2025. Nature microbiology. 10:681-693.DOI 10.1038/s41564-025-01932-w
- Lozanovski et al. 2020. Investigational new drugs. 38:776-784.DOI 10.1007/s10637-019-00826-z